Alloreactive NK cell therapy(Green Cross Corporation)(Alloreactive NK cell therapy(Green Cross Corporation))

概要

基本信息

药物类型

细胞疗法

别名-

靶点-

作用方式-

作用机制

细胞替代物

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病

在研适应症-

非在研适应症

淋巴瘤实体瘤

原研机构

Green Cross Co., Ltd.

在研机构-

非在研机构

Green Cross Co., Ltd.

权益机构-

最高研发阶段无进展临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 Alloreactive NK cell therapy(Green Cross Corporation) 相关的临床试验

IRCT20200417047113N1

/ Recruiting临床1/2期

Evaluating the safety and efficacy of allogeneic NK cells on COVID-19 induced pneumonia, double blind, randomized clinical trial

开始日期2020-04-27

申办/合作机构-

NCT01212341

/ Completed临床1期IIT

A Phase I Study of Allogeneic NK Cell Therapy in Patients With Refractory/Relapsed Lymphoma or Solid Tumor

Allogeneic natural killer (NK) cells (MG4101) were manufactured from normal healthy donor who underwent leukapheresis. These cells were processed based on a novel method for ex vivo activation and expansion using an irradiated and activated autologous feeder cell system. MG4101 has anti-tumor activities against various tumors including malignant lymphomas in vitro as well as in vivo tumor model.

开始日期2010-09-01

申办/合作机构